Clinical Trials on Hemangioendothelioma in New Zealand

Total 3 results

National Cancer Institute (NCI)

Completed

Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery

Locally Advanced Epithelioid Hemangioendothelioma | Metastatic Epithelioid Hemangioendothelioma | Unresectable Epithelioid Hemangioendothelioma

United States
Ikena Oncology

Recruiting

Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors

Solid Tumor | Solid Tumors, Adult | Malignant Pleural Mesothelioma (MPM) | Epithelioid Hemangioendothelioma (EHE) | NF2 Deficient Mesothelioma | Other NF2 Deficient Solid Tumors and Solid Tumors With YAP1/TAZ Fusion Genes | NF2 Deficiency | YAP1 or TAZ Gene Fusions

United States, United Kingdom
National Cancer Institute (NCI)

Completed

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

Recurrent Uterine Corpus Sarcoma | Chondrosarcoma | Recurrent Osteosarcoma | Gastrointestinal Stromal Tumor | Clear Cell Sarcoma of the Kidney | Metastatic Osteosarcoma | Ovarian Sarcoma | Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage III Uterine Sarcoma | Stage IV Adult... and other conditions

United States

3

Subscribe